1I4 Stock Chart & Stats
€0.02
<€0.01(10.00%)
At close: 4:00 PM EST
€0.02
<€0.01(10.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)4.83K
Market Cap
€26.59M
Enterprise Value€39.94
Total Cash (Recent Filing)€2.03M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume0
30 Day Avg. Volume4,833
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginGross margin recovery to about 60% in 2023–2024 shows the offering can generate meaningful contribution after direct costs. If maintained, this provides a foundation for future operating leverage, although current losses show that scale and overhead absorption remain unresolved.
Deleveraged Balance SheetReaching zero debt with positive equity of about $0.6M materially reduces leverage pressure compared with 2021. A less debt-burdened structure can preserve financial flexibility and reduce refinancing exposure, though the sharply smaller equity base still limits resilience.
Defined Women’s Health FocusThe focused model aligns product development around recurring maternity and female-health needs, which can help build a coherent platform rather than a diffuse offering. Its durability depends on converting that focus into revenue and operating scale.
Bears Say
Persistent Operating LossesPersistent losses and deeply negative operating and net margins, including roughly -14% net margin in 2025, show that gross-margin recovery has not translated into operating profitability. Continued losses can constrain reinvestment, weaken equity, and prolong dependence on external funding.
Ongoing Cash BurnOperating and free cash flow have been negative in every year shown, so the business continues to consume cash in normal operations. Even with improved 2025 burn, the absence of sustained positive cash generation raises ongoing funding and liquidity pressure.
Revenue ContractionRevenue remains volatile and contracted about 5% in 2025 versus 2024, after a slight decline in 2024 versus 2023. A shrinking top line makes it harder to absorb fixed costs, achieve operating leverage, and convert improved gross margins into sustainable earnings.
HeraMED Ltd. News
1I4 FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest stock price was €0.01 and its highest was €0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is €26.59M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 176 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Aug 21, 2026. The company reported >-€0.001 earnings per share for the quarter.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,158,636,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of >-€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in DE:1I4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:1I4 Sentiment 62%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
114.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HeraMED Ltd.
HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Uscom Limited
―
Atomo Diagnostics Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―